☆ 4.8 Article

GPRC5D-Targeted CAR T Cells for Myeloma

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Related references

Note: Only part of the references are listed.

Article Oncology

Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up

Thomas Martin et al.

Summary: PURPOSECARTITUDE-1, a phase Ib/II study, evaluated the safety and efficacy of Ciltacabtagene Autoleucel in heavily treated patients with relapsed/refractory multiple myeloma. The study showed early, deep, and durable responses at 12 months, with updated results at 2 years. Patients received a single infusion of Ciltacabtagene Autoleucel and responses were assessed.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Add to Collection

Article Oncology

Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies

Adam D. Cohen et al.

Summary: This study assessed the associated factors for movement and neurocognitive treatment-emergent adverse events (MNTs) in patients with multiple myeloma treated with cilta-cel. Strategies were implemented to monitor and manage patients with MNTs, leading to a significant reduction in the incidence of adverse events.

BLOOD CANCER JOURNAL (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy

Oliver Van Oekelen et al.

Summary: The study presents a case of a multiple myeloma patient who developed parkinsonism symptoms after receiving BCMA-targeted CAR-T cell therapy, highlighting the importance of close neurological monitoring for patients on such therapies.

NATURE MEDICINE (2021)

Add to Collection

Letter Medicine, General & Internal

Five-Year Outcomes for Refractory B-Cell Lymphomas with CAR T-Cell Therapy

Elise A. Chong et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

Nikhil C. Munshi et al.

Summary: The phase 2 study confirmed the efficacy and safety of ide-cel in patients with relapsed and refractory myeloma, with a majority of patients achieving responses and 26% achieving MRD-negative status. Despite the high response rate, almost all patients experienced grade 3 or 4 toxic effects, including hematologic toxic effects and cytokine release syndrome.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Ciltacabtagene autoleucel, a B-cell maturation antigendirected chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

Jesus G. Berdeja et al.

Summary: The study aimed to evaluate the safety and clinical activity of cilta-cel in patients with relapsed or refractory multiple myeloma, and the results showed that cilta-cel treatment achieved good efficacy and safety with short treatment duration, deep response, and long duration of response.

LANCET (2021)

Add to Collection

Article Hematology

A T-cell-redirecting bispecific G-protein-coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma

Kodandaram Pillarisetti et al.

BLOOD (2020)

Add to Collection

Review Medicine, General & Internal

Emerging immunotherapies in multiple myeloma

Urvi A. Shah et al.

BMJ-BRITISH MEDICAL JOURNAL (2020)

Add to Collection

Article Cell Biology

GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells

Eric L. Smith et al.

SCIENCE TRANSLATIONAL MEDICINE (2019)

Add to Collection

Article Hematology

ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells

Daniel W. Lee et al.

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)

Add to Collection

Article Medicine, General & Internal

Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia

Jae H. Park et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Article Medicine, General & Internal

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

S. L. Maude et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Article Medicine, General & Internal

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

S. S. Neelapu et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Article Hematology

MRD detection in multiple myeloma: comparison between MSKCC 10-color single-tube and EuroFlow 8-color 2-tube methods

Mikhail Roshal et al.

BLOOD ADVANCES (2017)

Add to Collection

Review Oncology

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

Shaji Kumar et al.

LANCET ONCOLOGY (2016)

Add to Collection

Article Hematology

GPRC5D is a promising marker for monitoring the tumor load and to target multiple myeloma cells

Yossi Cohen et al.

HEMATOLOGY (2013)

Add to Collection

Article Medicine, General & Internal

Overexpression of G protein-coupled receptor 5D in the bone marrow is associated with poor prognosis in patients with multiple myeloma

Johanna Atamaniuk et al.

EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2012)

Add to Collection

Article Multidisciplinary Sciences

An anatomically comprehensive atlas of the adult human brain transcriptome

Michael J. Hawrylycz et al.

NATURE (2012)

Add to Collection

© Peeref 2019-2024. All rights reserved.